Granted Patent B2

US 9,480,682 · App. 14/641,707 · Granted Nov 1, 2016

Abstract

Claims (14)

1. A method for treatment of Fabry disease in a patient in need thereof, the method comprising administering to the patient a formulation comprising 150 mg of 1-deoxygalactonojirimycin or a salt thereof every other day.

2. The method of claim 1 , wherein the formulation is administered for at least 2 weeks.

3. The method of claim 1 , wherein the salt of 1-deoxygalactonojirimycin comprises migalastat hydrochloride.

4. The method of claim 1 , wherein the formulation comprises an oral dosage form.

5. The method of claim 4 , wherein the oral dosage form comprises a tablet, a capsule or a solution.

6. The method of claim 1 , wherein the formulation comprises an injectable solution.

7. The method of claim 6 , wherein the injectable solution comprises a carrier comprising water, an aqueous saline solution, an aqueous dextrose solution or an aqueous glycerol solution.

8. The method of claim 7 , wherein the carrier comprises a sterile liquid.

9. The method of claim 1 , wherein the 1-deoxygalactonojirimycin or salt thereof enhances α-galactosidase A activity.

10. A method for treatment of Fabry disease in a patient in need thereof, the method comprising administering to the patient a formulation comprising 1-deoxygalactonojirimycin or a salt thereof, wherein the 1-deoxygalactonojirimycin or salt thereof is administered to the patient in an amount of 150 mg every other day for at least 2 weeks.

11. The method of claim 10 , wherein the 1-deoxygalactonojirimycin or salt thereof is administered orally.

12. The method of claim 10 , wherein the 1-deoxygalactonojirimycin or salt thereof is administered by injection.

13. The method of claim 10 , wherein the salt of 1-deoxygalactonojirimycin comprises migalastat hydrochloride.

14. The method of claim 10 , wherein the 1-deoxygalactonojirimycin or salt thereof enhances α-galactosidase A activity.

Assignments (10)